The extracellular matrix (ECM) of articular cartilage is comprised of complex networks of proteins and glycoproteins, all of which are expressed by its resident cell, the chondrocyte. Cartilage is a unique tissue given its complexity and ability to resist repeated load and deformation. The mechanisms by which articular cartilage maintains its integrity throughout our lifetime is not fully understood, however there are numerous regulatory pathways known to govern ECM turnover in response to mechanical stimuli. To further our understanding of this field, we envision that proteomic analysis of the secretome will provide information on how the chondrocyte remodels the surrounding ECM in response to load, in addition to providing information on the metabolic state of the cell. In this review, we attempt to summarize the recent mass spectrometry-based proteomic discoveries in healthy and diseased cartilage and chondrocytes, to facilitate the discovery of novel biomarkers linked to degenerative pathologies, such as osteoarthritis (OA).
Introduction
To gain a deeper understanding of the mechanisms that drive osteoarthritis (OA), it is important to appreciate the underlying biology of healthy and diseased joint tissues. Of interest is the pathophysiology of articular cartilage, and the processes that govern synthesis and organisation of extracellular matrix (ECM) components secreted by chondrocytes into the pericellular milieu. The chondrocyte is the unique resident cell of articular cartilage and thus solely responsible for ECM composition and regulation. Chondrocyte metabolism is influenced by its micro-environment, and in return influences ECM composition, organization and ultimately the mechanical resilience of cartilage 1e3 . As such, chondrocytes play a key role in ECM remodelling in physiological and pathological conditions 4 .
It is commonly established that healthy articular chondrocytes change into different phenotypes as OA develops and progresses:
(i) A catabolic phenotype develops, associated with an increase in proteolytic enzymes and reactive oxygen/nitrogen species, in response to mechanical stress and inflammatory cytokines, tumour necrosis factor (TNF)-a and interleukin (IL)-1b, leading to further ECM degradation. (ii) An anabolic phenotype emerges that is associated with regeneration of the ECM, including increased collagen type II and proteoglycan expression regulated by growth factors (transforming growth factor (TGF)-b, bone morphogenetic protein (BMP)s and insulin growth factor (IGF)-I), expressed either by the surrounding joint tissue or by the chondrocytes themselves. (iii) A hypertrophic phenotype develops, manifesting in expression of type X collagen and induction of apoptosis, ultimately resulting in osteophyte formation. (iv) A fibroblastic-like phenotype with an increased number of dedifferentiated chondrocyte and expression of type I collagen. (v) Lastly, a chondroblastic phenotype emerges with expression of foetal type IIA collagen, type III collagen and early/late differentiation markers 5 .
The specific phenotype that any individual chondrocyte exhibits is dependent on the zone in which the chondrocyte is situated and the stage of OA progression. In the upper zone, cellular proliferation and hypertrophy are observed, whereas the mid and deep zones display increased expression of type II collagen 6 . As OA progresses, cartilage is lost and chondrocytes undergo senescence, due to a combination of replicative exhaustion and oxidative stress 7 . Eventually, chondrocytes will undergo apoptosis, and the articular cartilage will be destroyed. The ultimate goal of mass spectrometry-based proteomics strategies is the identification of a specific tissue-derived secretome that is unique to the diseased chondrocyte and surrounding ECM and is able to distinguish between healthy and diseased cartilage.
Because protein expression is dependent on environmental conditions, the secretome is highly dynamic in composition and turnover. In 2010, Agrawal et al. suggested defining the secretome as "the global group of secreted proteins into the extracellular space by a cell, tissue, organ, or organism at any given time and conditions through known and unknown secretory mechanisms involving constitutive and regulated secretory organelles" 8 . In this narrative review, we only considered the chondrocyte (or cartilage) as the source of secreted proteins, which have been uncovered by state-of-the-art mass spectrometry-based proteomics techniques. Proteomic techniques include different methods, all relying on the separation of proteins and their further analysis using either gel-based (Two-dimensional electrophoresis) or gel-free methods. Protein separation methods are coupled to a mass spectrometer for identification of sequence by mass spectrometry 9, 10 . In differential analysis, the peptides may be marked with stable isotope at various stages of the analysis process, or Label-free methods could be performed. Several modes of analysis are available in mass spectrometry 10 . They differ markedly by the ionization source of the sample. The main sources used in proteomic analysis are matrixassisted laser desorption/ionization (MALDI) and surfaceenhancer laser desorption/ionization (SELDI) 10, 11 . These techniques allow a soft ionization of molecules without excessive fragmentation 9, 11 . More than the total tissue protein extract, it is expected that well-defined protein fractions such as the secretome could be a source of novel OA biomarkers, with the potential to predict disease severity and monitor progression.
Materials and methods
A literature search was performed in Pubmed/Medline and Scopus, identifying articles published between January 2004 and March 2016. Keywords used in 'Any fields' were; (chondrocyte OR cartilage) AND secretome (19 relevant papers out of 38 found), or (chondrocyte OR cartilage) AND (proteomic OR mass spectrometry) (65 articles relevant papers out of 290 found). Only results from mass spectrometry-based studies were included in this article. The review has considered all species, even if the majority of studies have been performed on human source of chondrocytes or cartilage. Only research articles published in English were included. Supplementary files of all papers were analysed and included in this review.
Chondrocyte secretome
Recent mass spectrometry-based proteomic studies have identified several proteins which form the chondrocyte secretome. In this part of the review, we focused on proteins identified either directly in the secretome of cartilage explants 12e20 or chondrocytes cultures 18,21e31 ), both of which are listed in Table I and illustrated in Fig. 1 . We further complete this list with proteins recently identified by proteomic analysis performed directly on fresh chondrocytes or cartilage tissue 32e36 (sometimes de-cellularized 37 ) whereby different locations in the joint were compared, or healthy joint tissues were compared with OA tissues. The characteristics of all these studies are summarized in Table II . Proteins have been classified in different sections: ECM proteins, cytokines and growth factors, enzymes and miscellaneous.
ECM proteins
As expected, the most abundant ECM proteins produced by chondrocytes, and detected by proteomic analysis, are collagens and proteoglycans, Table I . Thirteen collagens are found in the chondrocytes secretome, of which type II, VI and XII are the most abundant 35 . Collagen type XII is also known to interact with other cartilage elements such as cartilage oligomeric matrix protein (COMP), decorin and fibromodulin
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. Collagen type II and VI levels are increased in the secretome of chondrocytes taken from the medial condyle of patients with early OA (Mankin score 0e3), compared with samples taken from patients with severe OA (Mankin score 5e10) 25 . Beside the collagens, other ECM proteins found in high abundance in the chondrocyte secretome include; aggrecan, HPLN-1 (proteoglycan link protein), biglycan, COMP, fibronectin, prolargin (Proline-arginine-rich end leucine-rich repeat protein (PRELP)), matrilin-3, cartilage acidic protein-1 (CRTAC1 or ASPIC), latenttransforming growth factor beta-binding protein-1 (LTBP1), extracellular matrix protein-1 (ECM-1), tenascin, lubricin and chitinase-3-like protein 1 (CHI3L1), also known as YKL-40). CHI3L1 was found at lower levels in cartilage explants treated with IL-1b compared to controls 12 . CHI3L1, is a biomarker of OA found in synovial fluid and serum 39 , and plays a role in tissue remodelling and inflammation.
The concentration of CHI3L1 in OA synovial fluid positively correlates with levels of matrix metalloproteinase (MMP)-1, MMP-3, IL-6 and IL-17. IL-6 and IL-17 enhanced CHI3L1 production in human primary chondrocyte cultures 40 and CHI3L1 serum concentration positively correlated with osteophyte size in OA patients 41 . This protein is more abundant in knee compared to hip cartilage 37 and in OA compared to healthy cartilage 27 and is considered to be an early OA biomarker in the Stenberg' proteomic study, which compared early and severe OA secretomes 25 . In comparison with normal cartilage explants, CRTAC1 is found elevated in the OA cartilage secretome 13 . This protein is considered a cartilage specific protein, appearing early during chondrocyte differentiation of mesenchymal stem cells (MSCs) 26 . Expression of CRTAC1 allows discrimination between human chondrocytes and osteoblasts, or MSCs, in monolayer cell culture 26, 42 . This protein is therefore considered a good marker of chondrocytic differentiation of MSCs. LTBP1 also seems to be an important ECM protein secreted early in the differentiation of MSCs to chondrocytes 26 . Beside its structural role in the ECM, this protein is involved in the storage and the activation of TGF-b1, and therefore may play an important role in facilitating cartilage homeostasis. ECM-1 is a protein involved in endochondral bone formation serving as a negative regulator of bone mineralization 43 . It is able to enhance the proliferation of endothelial cells during angiogenesis 44 and inhibit MMP-9 proteolytic activity 45 . Louridos et al.
observed that the level of ECM-1 secreted by cells originating from damaged OA cartilage is 3-fold higher than that of healthy cartilage 13 .
Periostin secretion from explants increases with cartilage degradation 13 , and was only found in cultured OA chondrocytes 35 . Expression of periostin was previously shown to be elevated in OA cartilage compared to normal, and located in the pericellular ECM close to damaged areas of cartilage 46, 47 . Periostin is able to increase expression of IL-6, IL-8, MMP-1,-3,-13 and a disintegrin and metalloproteinase with thrombospondin motifs (ADAMTS)-4 by chondrocytes in vitro 46, 47 . Fibronectin and fibromodulin are secreted at comparable levels by OA and normal chondrocytes, but fragmentation of these ECM proteins is found to differ depending on whether the cell is healthy or diseased 36, 48 .
Cytokines and growth factors
Classical cytokines and chemokines like IL-6, IL-8, CCL8-20, CXCL1-3-5-8, CSF-1 are detected by tandem mass spectrometry only after an IL-1b stimulation of chondrocytes, cultured either in explant or in monolayer 12, 14, 19, 22, 27 . The IGFBP family is widely represented in chondrocyte secretome by IGFBP-2,-3,-4,-5,-6 and -7 12,21,22,24e27 . Expression of IGFBP-3,-4,-6 and -7 is increased in early OA 25 . These proteins serve as a carrier protein for IGF-1 and modulate the availability of IGF-1 to bind its receptor. Furthermore, IGFBP3 is known to induce chondrocyte apoptosis during OA 49 . In contrast IGFBP5 that has a positive role in cartilage anabolism, and inhibits enzymatic degradation; in fact IGFBP5 promotes cartilage extracellular matrix formation in vivo in the DMM OA rat model 50 .
Among growth factors detected in the chondrocyte secretome, gremlin-1, chondromodulin and pleiotrophin are known to be involved in hypertrophic differentiation regulation. Gremlin-1 is a BMP antagonist presenting reduced secretion from OA chondrocytes compared to normal 14, 35 , and plays an important role in bone development by inhibiting bone formation 51 . Gremlin-1 is therefore, potentially, a potent inhibitor of chondrocyte hypertrophy in cartilage. Chondromodulin is also important for chondrocytes stabilization, acting by inhibiting hypertrophic differentiation, and is shown to be secreted only by superficially located chondrocytes 34 . Pleiotrophin is a secreted heparin-binding peptide expressed in mesodermal and neuroectodermal cells during development, but rarely in adult tissues. Pleiotrophin is abundant in foetal and juvenile cartilage, but not in mature. Furthermore, pleiotrophin is re-expressed in chondrocytes in early OA, and is involved in the clustering and proliferation of chondrocytes observed in the early stages of OA 52 . Pleiotrophin is an inducer of hypertrophy during chondrogenic differentiation of MSCs 53 and is also a potent pro-angiogenesis factor.
Proteolytic enzymes and their regulators
Proteomic analysis of the chondrocyte secretome shows that the most abundant family of enzymes secreted is the MMPs, along with their endogenous inhibitors, the TIMPs. MMP-1 and 3, and TIMP-1, are particularly abundant. TIMP-3 appears to be more abundant in normal hip cartilage than knee, but MMP-1 is contrarily abundant in normal knee cartilage 37 . According to these studies, MMP-13 was only identified following IL-1b-stimulation 15 , or is at very low levels without stimulation 14 . With the exception of MMP-2 13 , MMP protein levels do not vary substantially between normal and OA chondrocytes, but all increase with IL-1b treatment. TIMP-1 and -2 levels are decreased in OA medial condyles 25 , and TIMP-1 is increased with TGF-b1 stimulation 24 . The other family of metalloproteinases expected to be found in cartilage is the ADAMTSs. Although ADAMTSs were found in some proteomic secretome studies 12, 22, 25 , they were not identified in all studies; most likely due to varying extraction methods which can eliminate ADAMTSs, along with the glycosaminoglycan (GAG) attachments of proteoglycans 15 . ADAMTS's may not be easily identified in mass spectrometry-based proteomic studies also due their relatively low abundance. Indeed, saturation of detectors with high abundance ions, type of protease used in mass spectrometry based studies (mainly trypsin) which may lead to non-identification of ionized peptides as they are too small, too large or contain amino acid sequences less likely to be 'seen' following ion identification. Positive studies, which identified ADAMTSs in the secretome, were all performed using OA chondrocytes or OA cartilage explant culture 12, 22, 25 . A recent study published by Svala, showed that peptides cleaved from aggrecan, following IL-1b stimulation in chondrocytes, were generated by MMPs, but not by ADAMTSs 14 . This finding confirms the importance of MMPs in cartilage ECM breakdown mediated by IL-1b. However, the fragmentation patterns, and differential distribution between cartilage and synovial fluid, are consistent with the existence of at least two proteolytic pathways for aggrecan degradation in human OA, generating both A further intriguing proteomic study was conducted to elucidate the target of MMPs and ADAMTSs in articular cartilage 20, 55 . Human articular cartilage 55 or crude equine cartilage proteoglycan extract 20 was digested by the addition of exogenous metalloproteases, including MMP-2, -3, -8, -9, -12, and -13 and the aggrecanases ADAMTS-4 and ADAMTS-5. Digestion products were identified by proteomic methods, and complete sequences of generated peptides were determined. A wide variety of peptides, originating from collagen types I, II, and III, biglycan, prolargin, fibromodulin, fibronectin, decorin, COMP, cartilage intermediatelayer protein, megakaryocyte-stimulating factor, clusterin, mimecan, aggrecan, and lumican, were obtained 20, 55 . MMP-2 was the most active protease used in the study, and the aggrecanases were the least active in generating peptides from cartilage digestion. The aggrecanases showed a preference for cleaving proteoglycancontaining proteins. However, all of the proteases cleaved many types of cartilage ECM proteins 55 . Interestingly, IL-1b treatment generated many COMP neopeptides 14, 20 . Some biglycan and COMP neopeptides were identified as being generated by ADAMTS-4 or MMP-3 and even increased by IL-1b concerning COMP 20 Proteomics studies also highlight a serine protease, HTRA1, as one of the most abundant secreted protein by chondrocytes. This enzyme cleaves aggrecan, within the interglobular domain, in human cartilage 57 . Levels of HTRA1-generated aggrecan fragments, containing the VQTV (356) neoepitope, were significantly elevated in OA cartilage compared with cartilage from healthy joints; implicating HTRA1 as a critical protease involved in proteoglycan turnover and cartilage degradation during degenerative joint disease 57 . Cleavage of aggrecan by HTRA1 was strongly enhanced by HTRA1 agonists such as CPII, a C-terminal hexapeptide derived from the C-propeptide of procollagen IIa1
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. HTRA1 is preferentially localized in the deep layer of cartilage 34 and increased during chondrocyte differentiation of MSCs
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, and by TGF-b1 stimulation 24 . HTRA1 is reduced 4-fold in OA vs normal chondrocytes 35 , with no difference detected between OA and normal decellularized cartilage 37 . Procollagen C-endopeptidase enhancer (PCOLCE)-1, and 2, are proteins which enhance procollagen C-proteinase activity, commonly identified in many proteomic studies. Furthermore, the C-terminal processed domain of PCPE (CT-PCPE) may have metalloproteinase inhibitory activity. PCOLCE1 is increased during chondrocyte differentiation of MSCs 26 and in OA cartilage 37 , but is decreased with IL-1b 14, 15 and with TGF-b1 24 . Other enzymes that could be important in the regulation of collagen metabolism are the procollagen-lysine, 2-oxoglutarate 5-dioxygenases 1 and 2. Expression of these enzymes is increased upon IL-1b stimulation 22, 58 , and they could be responsible for an over glycosylation of collagen fibrils, observed in OA, which decreases fibril flexibility 58 . Another set of enzymes found to be greatly increased in the OA chondrocyte secretome are the lysosomal enzymes, including cathepsins, phospholipases, peroxiredoxins, ovochymase-1 36, 37 . In fact, cathepsin activity based probes have detected increased cathepsin B activity in blood and synovial fluid of early OA patients, while cathepsin S was associated with RA 59 .
Other enzyme families detected in chondrocyte secretome comprise of SERPINs, superoxide dismutases (SODs), triosephosphate isomerase and lysozyme C enzymes. These are modulated by IL-1b, but are not significantly modified with the disease, except SERPINA3. SERPINA3, also known as a1-antichymotrypsin, is mainly located in the superficial layer of the articular cartilage 34 and is decreased during OA 35 .
Miscellaneous secretome proteins
The chondrocyte secretome contains many proteins involved in cellular regulatory pathways, cellecell or cell-ECM interactions, including chaperons, alarmins, apolipoproteins and chondrocalcin. Chondrocalcin is the C-terminal of type II collagen, associated with the calcification of cartilage ECM.
Gelsolin, clusterin and transforming growth factor-betainduced protein ig-h3 (TGFВІ) appeared in nearly all secretome studies and are one of the most highly secreted proteins by chondrocytes 14e19, 22, 24, 26, 30, 34, 35, 37 . Gelsolin is increased in OA compared to normal chondrocytes 35, 37 . Clusterin inhibits protein aggregation and apoptosis. This protein is detected more in healthy than osteoarthritic cartilage 37 . TGFBI is known to be involved in the interaction of the cell with type II collagen, and plays an important role in endochondral bone formation. Indeed, this factor is an inhibitor of mineralization. It was found to be highly secreted by OA chondrocytes, compared to normal chondrocytes 13 , and present at a greater abundance in hip OA than healthy cartilage 33 . Osteonectin is involved in ECM-cytokine interactions. Similar to osteopontin, osteonectin is highly secreted in deep layer chondrocytes 34 , and found to be increased in the secretome of medial condylar early OA cartilage 16, 25, 27 . TGF-b1 decreases the production of osteonectin 24 . Finally, thrombospondin-1,-3,-4 are all involved in cell-ECM interaction and angiogenesis, and are also secreted by chondrocytes 13, 14, 17, 19, 21, 24, 32, 34, 35, 37 . They are more abundant in the superficial layer of cartilage 34 . Thrombospondin-3 is increased in OA compared to normal chondrocyte secretomes 13 , and thrombospondin-1 is increased with IL-1b treatment 19 .
Discussion
The "omics" approach is a general exploratory approach used to investigate alterations in an enormous number of genes, transcripts, proteins, lipids and metabolites, in healthy vs diseased tissues. The challenge of using this approach is to identify those candidates that are specifically involved in the disease process. The most commonly used omics approaches include genomics, proteomics, lipidomics, metabolomics and transcriptomics. Such "omics" technologies applied to serum or urine samples have uncovered numerous new biomarkers, which are ubiquitous molecules in most cases. Therefore, it would be beneficial to refine "omics" technologies specifically to joint tissues (cartilage, bone, meniscus, synovial membrane) and compare "omics" profiles of the various articular tissues taken at different stages of evolution and correlate those amongst the various diseased tissues for the joint. In particular, the secretome of chondrocytes is of great interest because this approach provides a range of biomarkers reflecting the metabolic changes occurring in the main tissue affected by OA. Further, by investigating the chondrocyte secretome we increase the chance of identifying a circulating biomarker specific to disease, even specific to a particular joint. In this paper, we have reviewed and summarized data produced by proteomic analysis of cartilage or chondrocyte culture supernatants. Interestingly, some proteins have been found to increase in the secretome of OA explants or OA chondrocytes, while few were found decreased in comparison with normal secretome. Among these, some have been found in synovial fluid, serum or urine and proposed as potential biomarkers. For example, type II collagen 60e64 , aggrecan 63, 65, 66 , lumican 67, 68 , COMP 64, 66 , gelsolin 67, 69 , fibulin-3
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, mimecan 69 , periostin 13, 71, 72 , SERPINs 67, 70, 73 are found in these fluids in their native form, but also posttranscriptionally modified and/or fragmented. Some of these proteins or protein fragments have demonstrated to be burden of disease, prognostic, and efficacy of intervention or diagnostic soluble biomarkers, according the Burden of Disease, Investigative, Prognostic, Efficacy of Intervention and Diagnostic (BIPEDS) criteria. Some peptides generated during type II collagen degradation have been particularly well investigated, because type II collagen is the most specific protein of cartilage. Further, their concentration appears to be modified in joint disease. As previously mentioned, many aggrecan neoepitopes are found in cartilage tissue, but those generated by aggrecanases are largely released from cartilage and found in blood circulation, while the majority of fragments generated by MMPs remain entrapped in the tissue 54 .
Although the proteomic approach is a good approach to study secretome, there are some limitations associated with this method. Quantitative assessment of proteins secretome using these proteomic techniques remain hazardous, because the method promotes the quantification of some proteins relative to their solubility, binding to other components, their size, length, amino acid sequence and also their post-translational modifications. Small proteins, like cytokines, give few peptides after tryspinisation, and because at least 2 peptides are needed to assure the identification of the protein, they are probably excluded from the final observation.
In addition, there are some missing links in the secretome study. For example, there is to date few studies really dedicated and designed to investigate the dynamic kinetics of cartilage metabolism during OA disease. Most of the studies compare healthy and end-stage OA chondrocyte secretome, with the aim to discover new proteins secreted by the chondrocytes. For example, CRTAC1, HTRA1, PCOLCE, LTBP1, ECM-1, gremlin-1, clusterin, have been identified using this approach and now need more investigations to decipher their role in chondrocyte metabolism during OA pathogenesis.
The abundance of diverse models used in these proteomics studies also make them difficult to interpret. In monolayer, chondrocytes certainly have a different secretome than in their native 3D environment 31 . In explant culture, the majority of the newly synthesized proteins remains entrapped in the ECM and only degraded products are released into the supernatant 18 . Mechanical stimulation of the explant should be performed to mimic the physiological flow and help the protein to be released from tissue.
Posttranslational modifications like glycosylation, glycation, nitration are seldom investigated. A metabolomics approach would allow to investigate these changes and to complete knowledge coming from proteomic.
Many supposed cytoplasmic proteins are found in the chondrocyte secretome using proteomic technics. This finding seems surprising but can be explained by the secretion of ECM-derived vesicles by chondrocytes. Articular cartilage vesicles (ACVs) are 50e150 nm membrane-bound extracellular organelles found in normal articular cartilage. They were initially characterized in reference to their role in pathologic mineralization in cartilage in studies which mirrored those of matrix vesicles derived from growth plate cartilage and other normally mineralizing tissues. ACVs contain enzymes, ions and substrates necessary for mineral formation 74 . The presence of these ACVs explain why cytoplasmic/ membrane proteins, such as annexins, have been identified in the secretome of the chondrocytes. Transmembrane proteins can also be cleaved leading to the release in the extracellular space of extracellular part of the protein, which is the case of syndecans 75 .
Another explanation at the presence of membrane proteins in the secretome is the presence of apoptotic cells, mainly during OA 76e78 .
Loss of cell integrity during apoptosis further contribute to emerging proteins and pathway end-products in synovium and other bodily fluids, potentially giving rise to several biomarkers which may predict the susceptibility of an individual to develop OA. Pro-inflammatory cytokines, prostaglandins and reactive oxygen species (ROS) activate the normally quiescent articular chondrocytes and induce them to undergo a phenotypic shift through a phenomenon recently described as "chondrosenescence", leading to further disruption of homeostasis and metabolism in cartilage 7 . Effectively, chondrosenescence is the term that describes the agedependent deterioration of chondrocyte function and how it undermines cartilage function in OA. Until now, this particular phenotype has not yet been investigated by proteomic technics. This should be added in the research agenda.
In conclusion, proteomic analysis of chondrocytes secretome is a promising approach for detecting changes in chondrocyte metabolism linked to OA diseases (Table I ). This review listed the advantages and disadvantages of secretome investigation using the proteomic methods. The main limitation is the lack of standardization of the culture protocols, while the main advantage is the possibility to compare different environmental condition on the secretome. We have also suggested some research perspectives, including comparison of secretome at different disease stages. Definitively, research on secretome using proteomic methods have to be encouraged with the objectives to identify new biomarkers reflecting chondrocyte metabolic changes in OA.
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